Genome-wide association studies: how predictable is a person’s cancer risk?

@article{Roukos2009GenomewideAS,
  title={Genome-wide association studies: how predictable is a person’s cancer risk?},
  author={Dimitrios H Roukos},
  journal={Expert Review of Anticancer Therapy},
  year={2009},
  volume={9},
  pages={389 - 392}
}
  • D. Roukos
  • Published 1 April 2009
  • Medicine
  • Expert Review of Anticancer Therapy
From overenthusiasm to scientific assessment and hard reality, the time required for this transiton has recently been drastically shortened. As high-throughput screening technology is rapidly evolving, it allows for the testing of new conceptual study designs to manage highly complex diseases, such as cancer. Profiling the expression of thousands of genes simultaneously by microarrays created optimism a decade ago. It was thought that we could move away from an empirical, general, tumor–node… Expand
View on Taylor & Francis
ncbi.nlm.nih.gov
111 Citations
Background Citations
22
Methods Citations
1

111 Citations

Citation Type

Citation Type

Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
  • D. Roukos
  • Biology, Medicine
  • The Pharmacogenomics Journal
  • 2011
TLDR
The necessity of molecular networks modeling to understand complex gene–gene, protein–protein and gene–environment interactions is discussed, and the potential of systems clinico-biological approaches to predict intracellular signaling pathways components networks and cancer heterogeneous cells within an individual tumor is described. Expand
Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care
  • D. Roukos
  • Biology, Medicine
  • Expert review of molecular diagnostics
  • 2010
TLDR
This clinico–genome systems model opens the way for the discovery of new molecular innovations, both predictive markers and therapies, towards personalized treatment of cancer, by integrating clinical and genetics data into reverse engineering-based network modeling to approach the extremely complex genotype–phenotype map. Expand
Protein-altering germline mutations implicate novel genes related to lung cancer development
TLDR
The findings implicate germline genetic variants in ATM with lung cancer susceptibility and suggest KIAA0930 as a novel candidate gene for lung cancer risk. Expand
Novel clinico-genome network modeling for revolutionizing
TLDR
This clinico–genome systems model, published for the first time, opens the way for the discovery of new molecular innovations, both predictive markers and therapies, towards personalized treatment of cancer. Expand
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice.
TLDR
The intensive research effort for developing biomarkers could be chronologically classified into four fields: the use of traditional clinicopathologic features and environmental factors, including lifestyle, classic single-gene molecular research, preliminary genome-wide association studies and complete genome sequencing and molecular networks, which are currently being used. Expand
Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks
TLDR
How these new markers, added to current standard factors, could improve early breast cancer treatment decisions are evaluated, including age, tumor size, grade, hormone receptor status and HER2 status. Expand
Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour.
TLDR
Given the existence of a tight relationship between VTE and cancer, with both pathologies sharing biological pathways that allow one to promote the other, these SNPs constitute potential prognostic and predictive biomarkers currently needed for better management of cancer patients. Expand
The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case–control studies
TLDR
This meta-analysis confirms that XRCC3 rs1799794 is related to cancer risk, especially increased risk for breast cancer and thyroid cancer and reduced risk for ovarian cancer, however, well-designed large-scale studies are required to further evaluate the results. Expand
CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer?
TLDR
If the authors could identify high-risk individuals in the general population and subsequently tailor an effective preventive intervention, then they could protect them by saving their lives, and this achievement is now realistic, although it concerns a small only fraction of cases. Expand
Prognostic Significance of Host- and Tumor-related Factors in Patients with Gastric Cancer
TLDR
Research efforts are underway to identify either additional traditional risk factors or new prognostic and predictive biomarkers based on cancer genetics, genomics, and epigenetics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer.
  • D. Roukos
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
The 21-gene assay is a better recurrence predictor than the currently used Adjuvant!—a validated algorithm based on classical clinicopathologic features—and it can be used for tailoring chemotherapy among individual patients with hormone receptor (HR) –positive operable breast cancer. Expand
Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention
  • D. Roukos
  • Biology, Medicine
  • Expert review of molecular diagnostics
  • 2009
TLDR
There has been an explosion in biomedical research for the identification of genetic variation-based personalized management of complex diseases and potential highly effective, risk-guided prevention strategies could dramatically reduce incidence and mortality of the disease. Expand
Genome-wide association studies in cancer.
TLDR
Genome-wide association studies have been conducted in five of the commonest cancer types and have identified more than 20 novel disease loci, confirming that susceptibility to these diseases is polygenic. Expand
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
TLDR
A second genetic variant in the 8q24 region that, in conjunction with another variant recently discovered, accounts for about 11%–13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans is reported. Expand
Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery
  • D. Roukos
  • Medicine
  • Expert review of molecular diagnostics
  • 2008
TLDR
Combining established classic and new risk factors, including familial BRCA susceptibility to breast cancer, an integrated surgery-guided algorithm for clinical validity is proposed, and future genome-wide association studies larger than those currently available using newer genotyping platforms with more than 1 million single-nucleotide polymorphisms and copy number variants will complete the genetic map. Expand
Use of gene signatures to improve risk estimation in cancer.
TLDR
This is one of the largest studies in human cancer showing the ability of gene expression profiles to improve risk stratification beyond established risk assessment algorithms that take into account clinicopathological variables. Expand
Genome-wide association study identifies novel breast cancer susceptibility loci
TLDR
To identify further susceptibility alleles, a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls was conducted, followed by a third stage in which 30 single nucleotide polymorphisms were tested for confirmation. Expand
Multiple newly identified loci associated with prostate cancer susceptibility
TLDR
A genome-wide association study using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml) identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X. Expand
Multiple loci identified in a genome-wide association study of prostate cancer
TLDR
The findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals. Expand
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
TLDR
Four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer were identified and confirmed in 1,776 affected individuals and 2,072 controls from three additional studies. Expand
...
1
2
3
4
5
...